Sangamo's ST-920 demonstrates evidence of clinical benefit

Phase 1/2 research shows that treatment could be very effective against Fabry disease - News - PharmaTimes

Related Keywords

Cincinnati ,Ohio ,United States ,Robert Hopkin ,Nathalie Dubois Stringfellow ,Cincinnati Children Hospital Medical Center , ,Cincinnati Children ,Hospital Medical Center ,St 920 ,Sangamo ,Dabry ,